Arkolith/Insider Trading/SPRO/Form 4

Shukla Sath

Chief Financial OfficerSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Feb 3, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$17K
Net Open-Market Flow
-$17K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2023Sell(S)10K$1.83$17K313K
Feb 1, 2023Grant(A)266K—$0322K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-003945) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML